Preparation for treating and preventing alimentary anaemia in young pigs

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science and aims at treating and preventing alimentary anaemia in young pigs. A preparation contains an iron dextran complex, nanosized and zero-valent selenium (Se0), vitamin E, vitamin B12 and water in the following proportions, wt %: iron dextran complex 0.0001-80.0, selenium (Se0) 0.0001-5.0, vitamin E 0.0001-20.0, vitamin B12 0.0001-10.0, water for injections - the rest.

EFFECT: using the declared method provides compensating iron deficiency in young pigs, improving animal's growth and development, increasing total immunity and rapid adaptation to the varying ambient environment.

4 tbl, 4 ex, 4 dwg

 

The technical field to which the invention relates.

The invention relates to veterinary pharmacy, namely to the drug for the treatment and prevention of nutritional anaemia in piglets, and can be used in methods of prevention and treatment of iron deficiency diseases in piglets.

The level of technology

Known complex polysaccharide drug Horseferry, which makes up for the deficiency in piglets. The advantage of Horseferry is stable binding of iron by which achieves good local and General tolerability. Active ingredients: complex of polysaccharide and iron hydroxide (III) (iron 100 mg/ml), phenol (0.5 g/100 ml (see Eliseeva, E. Healthy young animals is the basis of prosperity farms / E. Eliseev // Pig. - 2008. No. 4. - S. 24-28).

The disadvantages of this drug are high cost and lack of vitamins.

Known iron preparation, which involves two intramuscular injection of iron supplementation in a dose of 2-8 ml/goal for the first 10 days of life animals (100-375 mg Fe). The proposed method replaces the re-injection of iron solution containing glycinate zinc, glycinate copper and potassium iodide (see U.S. Pat. RU # 2135173, IPC AC 31/295, AK 31/30, AK 31/315, AK 33/18 publ. 27.08.1999).

The disadvantages of this drug are high toxicity, nedostate the Nai absorption of iron.

Well-known drug for the prevention and treatment of iron deficiency anemia. The drug contains farbital, while further comprises gelatin in the following ratio, wt.%:

farbital80-99
gelatin1-20

(see U.S. Pat. RU # 2280457, IPC AC 33/26, AK 35/32, OR 7/06, publ. 27.07.2006).

The disadvantage of this method is poor digestibility.

Well-known drug for the prevention and treatment of anemia. The product provides in comparison with analogues, reducing the amount of the drug in the form of dextran and stability of aqueous solutions in a concentration of from 1 to 99% within 24 months. The drug contains Zhelezobeton and sorbitol in the following ratio, wt.%:

Zhelezobeton78-90
sorbitol10-22

(see U.S. Pat. RU # 2338516, IPC AC 31/047, AK 31/721, OR 7/06, publ. 20.11.2008).

The disadvantages of this drug are high toxicity, poor absorption of iron.

The known method of prevention and treatment of nutritional anaemia and prevention gipoplasticheskaya of anemia is irrigated. The method includes introducing food preparations containing iron. At the same time the piglets with 30 days advanced age of the animal is administered probiotic preparation - whey gidralizovanny in the amount of 2 ml per kilogram of body weight once a day as a prophylactic measure in 1 month. For therapeutic purposes whey gidralizovanny injected pigs within 2 months in the same doses. The method contributes to the normalization of microflora, activation of the enzymatic activity of the gastrointestinal tract by increasing bifidogenic factors that increase the digestibility of feed and biosupdate protein-mineral-vitamin complexes, administered in the feed (see U.S. Pat. RU # 2429863 IPC A61K 35/20, A61K 33/26, publ. 27.09.2011).

The disadvantages of this drug are high cost, lack of vitamins, lack of absorption of iron.

The closest in technical essence and the achieved positive effect and adopted by the authors for the prototype is a complex microelement drug Seimei, which normalizes metabolism, offsetting the deficit of iodine, selenium and iron in the body piglets (see Alekseev centuries, Arestova I. Y. features of the biochemical composition of the blood of pigs at destination Permit", "Calcifica-5" and "Sedimen®" //Bulletin of cgpu them. I. Yakovleva. - 2010. - №1 (65). - C. 4-70.

The drug composition: 1 ml contains

iron (in the form of iron (III) complex with dextran)16-20 mg
iodine5.5-7.5 mg
selenium0.07-0.09 mg

The disadvantages of this drug are low effect on the body, as well as increased sensitivity of pigs to geisterstreiber drugs on the background of vitamin E.

Disclosure of inventions

The task of the invention is the development of a drug for the treatment and prevention of nutritional anaemia in piglets, complementary iron deficiency in piglets, improving the growth and development of animals, improving the overall immunity and rapid adaptation to changing environmental conditions.

The technical result that can be achieved using the present invention is to replenish iron deficiency in piglets, to improve the growth and development of animals, increase General immunity and rapid adaptation to changing environmental conditions.

The technical result is achieved by using a drug for the treatment and prevention of nutritional anaemia in piglets, including zhelezobaktery complex, the village is in the nano state and zero valence (Se 0), vitamin E, vitamin b12and water in the following ratio of components, wt.%:

zhelezobaktery complex0,0001-80,0
selenium (Se0)of 0.0001 to 5.0
vitamin Eof 0.0001 to 20.0
vitamin b12of 0.0001 to 10.0
water for injectionrest

The entity receiving the drug for prevention and treatment of nutritional anaemia in piglets is as follows: the initial substance in wt.%, namely zhelezobaktery complex is 0.0001-80,0; selenium (Se0) of 0.0001 to 5.0; vitamin E is 0.0001 to 20.0; vitamin b12of 0.0001 to 10.0 and water for injection - the rest are mixed under aseptic conditions and Packed.

Pharmacological action of the drug is that replenishes iron deficiency, by entering from the outside, this creates the conditions for the accumulation of iron and the increase of its level in the blood plasma, bone marrow, arifullah.

Iron is an essential biochemical component in the key processes of metabolism, growth and cell proliferation. The exclusive role of iron is determined by the important biological the functions of proteins, which include this biometal. The most famous iron-containing proteins include hemoglobin and myoglobin. Apart from the latest iron is composed of a significant number of enzymes involved in energy production (cytochromes), DNA biosynthesis and cell division, detoxification products of endogenous decay by neutralizing reactive oxygen species (peroxidase, cytochrome C oxidase, catalase). The role of iron-containing proteins (ferritin) in the implementation of cellular immunity, the regulation of hematopoiesis. However, iron can be very toxic element, if present in the body in concentrations exceeding the capacity of the iron-containing proteins. The potential toxicity of free ferrous iron (FeII) because of its ability to start a chain of free radical reactions leading to lipid peroxidation of biological membranes and toxic damage of proteins and nucleic acids. The main value of stocks of iron in the body is that they allow the blood system to adequately respond to acute and chronic blood loss (see E. F. Morshchakova, A. D. Pavlov / Regulation of iron homeostasis // Haematology and Transfusiology: Scientific-practical journal. - 2003. No. 1. - S. 36-39).

Iron deficiency in the body which causes a variety of disorders of physiological functions: it reduces the level of oxygen carriers, violates the hematopoietic function of bone marrow, reduces the level of enzymatic redox and immune processes, can lead to premature birth, fetal underdevelopment, or efficacie, violation of labor activity. If the processes of iron absorption are violated, and iron stores are depleted, there is a state of iron deficiency and pathology develops - iron-deficiency anemia, violated enzyme, redox and immune processes (see Belous A. M. Physiological role of iron / A. M. Belous, K. T. Cavalryman. Kiev: Naukova Dumka, 1991. - 104 S.).

On average, it is estimated that by reason of this disease dies 20-25% of pigs or the three little pigs from each litter. It is assumed that 1/3 of the losses in pig production brings nutritional anemia (see Aliyev C. A., Ivanov D. P. New in the prevention and treatment of nutritional anaemia in piglets. - In the book: Prevention and treatment of diseases of young animals C. farm animals. - M.: Kolos, 1968, S. 222-243).

Modern breeds of domestic pigs are very prolific and have a high energy growth. The relative growth rate of pigs increases at the end of their womb and in the first month after birth (see Svechin K. B. Individual development of farm animals. - Ed. WASHA, Kiev, 1961).

If normally is developed Piglet is born with body weight of 1.1-1.2 kg, by the time of weaning, it may increase 16-20 times, and for 6-7 months in 50-60 times. Of all kinds of agricultural animals piglets in the first months after birth have the highest growth rate. Physiological maturity pigs under optimum conditions of feeding and housing comes to 10-11 months, and in 14-15 months, you may have to get a full litter (see Karpaty I. M., Abramov S. S., Shcherbakov,,, Levchenko C. I., I. P. Kondrashin, A. C. Korobov, M. P. Babin, A. P. Kurdeko, I. H. Sevryuk, S. L. Boronov; Internal non-infectious animal diseases: the textbook / under the editorship of Professor I. M. Karpati. - Mn.: Belarus, 2006. - 679-680 C.). The main cause of anemia is insufficient intake of iron in the organism of pigs. In newborn animals, the content of iron in the body is 48-50 mg. Need piglets in this trace element in the first weeks of life equal to 10-15 mg / day, and the milk of the sow contains only 0,899 mg/L. Therefore, the pig per day with milk of mother receives only 1-1,5 mg of iron, and his need is satisfied only by 12-15% (see Karpaty I. M., Abramov S. S., Shcherbakov,,, Levchenko C. I., I. P. Kondrashin, A. C. Korobov, M. P. Babin, A. P. Kurdeko, I. H. Sevryuk, S. L. Boronov; Internal non-infectious animal diseases: the textbook / under the editorship of Professor I. M. Karpati. - Mn.: Belarus, 2006. - 679-680 C.).

Even with abundant feeding sows is the courthouse square, containing iron, the amount of this trace element is not increased above a certain level. Less than 2% of the iron introduced into the body pregnant sows crosses the placenta and enters the fetus. Therefore, the minor, his stock available in the body of newborn piglets is quickly consumed, which leads to iron deficiency, obuslovlivanija anemia. So, the pig up to three weeks of age must 114 mg of iron, and he gets with his mother's milk for about 24 mg, therefore newborn animals in the first days of life is sharply reduced the amount of hemoglobin: from 10.7 mg to ml to 4.5 mg. So by 7-8 th day of life in piglets comes deficiency, and by 3-4 weeks of age signs of anemia reach the greatest severity.

Selenium - essential biologically active element for the human body. The trace mineral selenium plays an important role in growth of young animals, development and reproduction of animals, affects the processes of tissue respiration. Selenium is actively involved in various metabolic processes, provides antioxidant protection of animals, the activity of many redox enzymes and vitamins. The ability to inhibit the processes of lipid peroxidation explains its role in strengthening the natural resistance of the organism.

Bolshinstvesluchaev agree that selenium has a stimulating effect on the activity of the humoral immune system (see Fisinin, Century Natural minerals in animal and poultry feeding / Century Fisinin, P. Sooraj // Livestock Russia. - 2008. No. 9. - S. 62-63). There is evidence of involvement of selenium in immune reactions in the composition of selenoproteins, the metabolism of thyroid hormones, which allows you to use selenesetestcase drugs as Immunostimulants. The trace element selenium has a high biochemical activity (see Lukasova I., merenkova S. efficacy of the drug nutri selenium young cattle fattening pigs / Pig. - 2006. No. 1. - S. 14-16), while selenium taken in nano state and zero valence (Se0) for stabilizing the basis geisterstreiber complex, promotes rapid absorption of the drug and the intensification of metabolism in animals.

Vitamin E, as an active natural antioxidant, is deposited mainly in the liver and adipose tissue. It stops the formation of lipid peroxides in cell membranes, while maintaining their integrity and functional activity. Vitamin E is a component of biological membranes, forming them in complex with selenium and polyunsaturated acids. More than in the membranes of these acids, the more the need for vitamin E and selenium to support them and the activity. Keeping the fatty acids in the membranes of platelets, vitamin E prevents the formation of endoperekisey, precursors of prostaglandins, and this limits the processes of platelet aggregation. Vitamin E activates the synthesis of heme, which is a component of hemoglobin, myoglobin, catalase, peroxidases, cytochromes. Increasing the synthesis of heme, vitamin E activates erythropoiesis, the synthesis of respiratory enzymes in tissues and hence energy and synthetic processes.

Vitamin b12- cobalt containing compound. It regulates the process of hematopoiesis, the process transmediterranea choline, methionine, creatine, nucleic acids and nucleotides, as well as contributes to the accumulation in erythrocytes of compounds containing sulfhydryl groups. Methionine helps to increase the biological value of plant diets (promotes better assimilation of amino acids, vegetable proteins).

Vitamin b12is the growth factor, has a beneficial effect on the liver and nervous system. Vitamin b12involved in hematopoiesis, the synthesis of methyl groups, isomerization methylmalonic acid. These reactions are of great importance in the metabolism of amino acids and volatile fatty acids. Especially necessary for normal reproduction in sows, security prevents them ABO is you, allows you to get a healthy, well-developed piglets.

A brief description of the drawings and other materials

In Fig. 1 given the drug for the treatment and prevention of nutritional anaemia in piglets, the effect of the drug on the change of body weight of the rats (n=10), table 1.

In Fig. 2 - the same, hematological parameters of mice (n=10), table 2.

In Fig. - 3 is the same, biochemical parameters of blood serum of mice (n=10), table 3.

In Fig. 4 - the same, hematological indices and iron levels in the blood serum of piglets, table 4.

The implementation of the invention

Examples of specific performance gain drug for the treatment and prevention of nutritional anaemia in piglets.

Example 1. The entity receiving the drug for prevention and treatment of nutritional anaemia in piglets is as follows, the starting materials zhelezobaktery complex, selenium nano state and zero valence (Se0), vitamin E, vitamin b12and water in the following ratio of components, wt.%:

zhelezobaktery complex0,00001
selenium (Se0)0,00001
vitamin E0,00001
vitamin b 120,00001
water for injectionrest

The composition of the dosage form showed a slight increase in the percentage of iron in the organism of animals needed to prevent iron deficiency and insufficient activation of the antioxidant system of the organism, the activity of catalase in the blood of experimental rabbits increased by 1.14%, and the concentration of malondialdehyde decreased by 0.52%.

Example 2. Carried out similarly to example 1, but take the following ratio of components, wt.%:

zhelezobaktery complex20,0
selenium (Se0)3,0
vitamin E15,0
vitamin b127,0
water for injectionrest

The composition of the dosage form showed positive dynamics in animals. After 14 days, the activity of catalase and peroxidase in the blood of rabbits increased by 36.1% and 28.8%, respectively. The concentration of the percentage of iron in 5 days amounted to 10.3 ág%. Cholesterol the serum decreased by 10.5%, and the total protein content increased by 11.2%.

Example 3. Carried out similarly to example 1, but take the following ratio of components, wt.%:

zhelezobaktery complex80,0
selenium (Se0)5,0
vitamin E20,0
vitamin B1210,0
water for injectionrest

The composition of the dosage form also showed positive dynamics in animals. After 14 days, the activity of catalase and peroxidase in the blood of rabbits increased by 37.1% and 29.8%, respectively. The concentration of the percentage of iron in 5 days amounted to 11.3 mcg%. The content of cholesterol in blood serum decreased by 11.5%, and the total protein content increased by 12.2%.

Example 4. Carried out similarly to example 1, but take the following ratio of components, wt.%:

zhelezobaktery complex85,0
selenium (Se0)7,0
vitamin E 23,0
vitamin b12to 12.0
water for injectionrest

The increase in the concentration of selenium and geisterstreiber complex has led to the manifestation of toxic effects. So 5 days after use of the drug increased activity of aspartate aminotransferase and alanine aminotransferase by 12.9% and 10.3% respectively, also increased the content of total bilirubin by 9.7%, which indicates an increased load on the liver.

Thus, the optimal composition of the dosage form of the drug is the drug according to examples 2 and 3, which was tested on laboratory white mice, rabbits, pigs.

To determine the lethal doses of the drug used clinically healthy white mice weighing 20-22 g, studies are carried out according to the "guidelines for the Toxicological evaluation of new drugs for the treatment and prevention of non-contagious diseases of animals" (Institute of non-contagious diseases of animals, 1987).

Study of acute toxicity

Studies show that developed the drug in enteric (intestinal) the doses from 1041,66 to 6250,0 mg/kg (D. C.) body weight for white mice of visible clinical signs of toxicosis is. After Vvedenie,0 mg/kg in the first two hours of experience in mice was noted concern excitation and twitching of individual muscle groups. These changes were apparently a consequence of stress after insertion of the probe into the stomach. Gradually these phenomena are, and animals restored the previous activity.

Tested doses significantly superior therapeutic. A further increase in the input dose is not possible, because the maximum volume of the intragastric administration of drugs for white mice may not exceed 0.6 ml, so the exact values of MTD, LD50, LD100install was not possible. Against most of the administered dose of the drug to the intended therapeutic, therapeutic index is equal to 20.

As a result of researches it is established that the data of the drug on the degree of impact on the body in accordance with the standards of GOST 12.1.007-76 to the 4th class of hazard - low hazard substances.

The study of local action on the mucous membranes

The results of the staging of conjunctival tests on rabbits indicate that after installation of the drug's clinical condition of the animal remains within the physiological norm. There were no changes in the blood vessels of the conjunctiva, the presence of lacrimal and discharge state changes of the cornea and eyelids.

The study of the allergenic properties

Studies, which have when sensitization of animals by daily applications of drugs within ten days not observed any changes in the General condition of the animals, as well as local skin changes (edema, hyperemia, and others).

The study of chronic toxicity

Daily oral administration of iron-containing drug during the 30 days white rats at doses of 1.5 and 4.5 ml/kg of body weight does not cause changes in behavior and General condition of the animals. When comparing the total and average daily gains mass of rats experimental group, with rats in the control group, significant differences are not installed. Also there are no significant differences in the total and average daily weight gain of rats depending on the received dose (table. 1).

Study of the effect of the drug on hematological parameters of mice

The experiment was conducted on 30 clinically healthy nonlinear white laboratory mice-males weighing 25-30 g To assess the impact of the drug on hematological parameters of mice were divided into three equal groups; animals of the control group administered orally with saline at the dose of 1.5 ml/kg body weight, the first experimental group - oral test drug at a dose of 15 ml/kg of body weight (ten times therapeutic dose), the second - 1.5 ml/kg body weight (therapeutic dose). Through hasaw animals decapitat and blood collected for the study. All hematological and biochemical studies are carried out according to standard techniques (see Menshikov centuries Laboratory methods in the clinic. The Handbook. M: "Medicine", 1987. 368 S.).

Digital material is treated by methods of variation statistics. The reliability impact of a number of gradations of the studied factor (toxicant IEA) on hematological parameters were identified using the method of variance analysis univariate complexes of small groups (see Lakin, F. Biometrics. Manual for universities and pedagogical institutes. M: The High. school, 1973. 343). The reliability of differences determined by F-Fisher test. The difference is significant at p<0,05 (table. 2).

The analysis of the obtained results are not statistically significant differences in the number and the percentage of leukocytes, lymphocytes, monocytes in mice experimental and control groups. In the group of mice given a tenfold dose, statistically significant increase in the absolute number and the percentage of granular leukocytes, respectively 45.5 and 39.9%, and a decrease in the number of lymphocytes. Granulocytes are important for detoxification of different protein bodies, but also directly participate in allergic reactions.

Analyzing the obtained results, it can be noted positively the e impact of the introduction of the drug for the treatment and prevention of diseases, associated with iron deficiency for farm animals at a dose of 1.16 mg/kg of LW on some hematological indicators: increase in the number of erythrocytes, hemoglobin level, stabilization of the number of leukocytes. It is established that the introduction of the drug increases in mice the concentration of hemoglobin of 10.7% in the second group and 13.4% in the first, increases the number of erythrocytes, respectively 11.5% and 16.8%. This increases the average amount and the average concentration of hemoglobin in erythrocytes.

In the analysis of biochemical parameters of blood serum statistically significant increase of iron content in mice of the second experimental group 12.3 Μmol/l in mice of the third experimental group - 7.5 Μmol/L.

In the group of animals that received ten times therapeutic dose changes (table. 3).

The increase in the content of the end product of protein metabolism - creatinine 13.8% indicates increase energy metabolism in muscle and other tissues.

The use of the drug in a dose of 15.0 ml/kg increases in the blood of mice activity aspartaminotransferazy by 18.5%, and alanine aminotransferase by 21.9%. These results reflect a trend of increasing liver function in pereaminirovanii amino acids.

The increase of amylase by 13.1% and triglycerides by 19.6% indicates increasing function of the tion of the pancreas.

It is known that albumin is involved in mineral, pigment, hormonal and some other types of currency, regulating the content of free (non-protein fractions) of biologically important substances with higher activity. Thanks to this function, albumin plays a significant role in the implementation processes of detoxification, which explains the decrease in the second group by 19.7%.

The drug helps to increase the total protein content in mice of the second and third groups, respectively, 10,35 and made 13.36%. In the body's total protein performs the following functions: participates in blood clotting, maintains a constant blood pH, carries out the transport function (transfer of lipids, bilirubin, steroid hormones to the tissues and organs involved in immune responses.

Hepatocytes metabolize bilirubin only bound to albumin, as an indirect (free bilirubin is poorly soluble in water connection. Accordingly, a decrease in albumin in the blood decreases the uptake of bilirubin by hepatocytes, which leads to the accumulation of bilirubin in the blood of the mice of the second group within physiological values.

At necropsy, color, size, elasticity, and weight of internal organs of experimental and control mice were the same.

To study the effect of drugs is and hematological parameters of piglets

Clinical studies conducted on 60 pigs breed CM-1 at the age of 4-30 days. Animals were divided into three groups of 20 animals each. In the group of animals were selected on the basis of "analogues" (weight, conditions of feeding and housing). Each group of animals were formed from individual nests.

Animals of the 1st experimental group on day 4 of life once intramuscularly injected a drug in the dose of 1.5 ml per animal. Other ingredients: water solvent. The piglets of the second group, the drug is administered on day 4 of life once intramuscularly in the upper third of the thigh in a dose of 2 ml per animal is injected drug proferrin-100 containing 1 ml of 100 mg of iron in the form of iron-dextran-heptenophos acid. The piglets of the third group of drugs is introduced, and they served as a control.

During the experiment three times: at the age of 4, 15 and 30 days study some morphological and biochemical indices of the blood of pigs.

Studies on the blood of Guinea pigs is presented in table 4.

Study of some hematological parameters in experimental animals has allowed to establish that the piglets that received a drug and proferrin-100 throughout the study period, the average content of erythrocytes and hemoglobin levels increased gradually with age, are within the norm of the positive physiological values. At the same time, piglets from the first experimental group, these figures are slightly higher than the values of those pigs of the second group: the level of hemoglobin in the age of 15 days - 9.7% at the age of 30 days - by 7.3%. The number of erythrocytes in piglets of the first experimental group at the age of 15 days - 9.7% at the age of 30 days - 7.3% was higher than the same values in animals of the second group.

The control piglets at the age of 15 days the number of erythrocytes and the hemoglobin concentration corresponded to very low values, representing, respectively, 4,12+0,28×1012/l and 56.7±2.4 g/l, and continue to be at a low level to 30 days of age: 4,98+0,33×1012/l and 58,4±2.8 g/l

When studying the dynamics of the number of leukocytes in suckling piglets revealed the following: if experimental animals throughout the study period, the average content of leukocytes remained virtually unchanged, ranging normative physiological values, the piglets in the control group see progressive leukopenia, most pronounced at the age of 10-12 days, indicating that the inhibition of leucopoiesis and reducing the resistance of the body, characteristic of iron deficiency anemia.

The use of iron preparations warned sideropenic condition in the body experienced piglets, maintaining the content of the serum iron level normative physiological parameters. At the same time, during the whole period of the experiment, the serum iron content in the first group of pigs was compared with the animals of the second group, which impose horseferry, 26 days after injection - 11.8%.

Piglets from the control group, the level of iron in the serum for a specified period of time not reached physiological normative values, ranging from 11,4±0,4 to 13.6±0.4 µmol/l, respectively at 15 and 30 days of life, and erythropenia and hemoglobinemia and was accompanied by the development of clinical signs of iron deficiency anemia.

Thus, the approbation allows to conclude that the application of the developed drug is an effective way to prevent nutritional anaemia in piglets.

The present invention in comparison with the prototype and other known technical solution has the following advantages:

- replenishment of iron deficiency in piglets;

- improving the growth and development of animals;

- increase General immunity and rapid adaptation to changing environmental conditions.

- high prophylactic and therapeutic effect.

A drug for prevention and treatment of nutritional anaemia in piglets, including zhelezobaktery complex, selenium nano state and zero valence (Se0), vitamin E,vitamin b 12and water in the following ratio of components, wt.%:

zhelezobaktery complex0,0001-80,0
selenium (Se0)of 0.0001 to 5.0
vitamin Eof 0.0001 to 20.0
vitamin b12of 0.0001 to 10.0
water for injectionrest



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to a triazolopyridine compound of general formula [I] or a pharmaceutically acceptable salt, where the partial structural formula: is a group represented by any of the following formulae: or R1 is (1) a hydrogen atom, (2) C1-6alkyl group, (3) phenyl group or (4) C3-8cycloalkyl group; R2 is (1) a hydrogen atom, (2) C1-10alkyl group, (3) phenyl group, optionally substituted with identical or different 1-3 substitutes selected from the following groupB, (4) C3-8cycloalkyl group, (5) C3-8cycloalkenyl group, (6) thienyl group, optionally substituted with 1 substitute selected from halogen or C1-6alkyl group, (7) phenyl-C1-6alkyl group (wherein phenyl is optionally substituted with different or identical 1-2 substitutes selected from halogen, C3-8cycloalkyl or halogen-C1-6alkyl group) or (8) C3-8cycloalkyl-C1-6alkyl group; R3 is (1) a hydrogen atom, (2) a halogen atom, (3) C1-6alkyl group, (4) phenyl group (6) phenyl-C1-6alkyl group; and each of R4 and R5 are both hydrogen atoms or a group B: (a) a halogen atom, (b) C1-6alkyl group, (c) C3-8cycloalkyl group, (d) cyano group and (e) halogen-C1-6alkyl group. The invention also relates to the specific compounds, a pharmaceutical composition based on the compound of formula [I] and to use of the compound with the formula [I].

EFFECT: obtaining novel triazolopyrine compounds, having inhibitory activity on prolyl hydroxylase and capable of inducing erythropoietin production.

30 cl, 34 tbl

FIELD: veterinary medicine.

SUBSTANCE: method of normalisation of the thrombin time duration in newborn calves with iron deficiency anemia consists in the fact that ferroglukin 150 mg (2 ml) intramuscularly is prescribed to newborn calves with iron deficiency anemia, twice with the interval of 4 days, cresacyne 5 mg/kg per day, including it in the scheme of watering for 4 days, starting simultaneously with the first injection of ferroglukin and gamavit intramuscularly once a day in the morning of 0.05 ml/kg for 4 days, starting simultaneously with ferroglukin and cresacyne.

EFFECT: acceleration of normalisation of thrombin time duration, enables to reduce the risk of vascular complications in newborn calves with iron deficiency anemia, to revitalise the herd, to reduce mortality, to maintain the volume and quality of the meat and dairy products obtained from animals.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to clinical pharmacology and veterinary therapy. The method consists in administering the complex iron-dextran preparation Ferranimal-75M intramuscularly on the 5th day of calf's life in a dose of 3 ml in a combination with an intramuscular injection of the preparation Hydropeptone in a dose of 10 ml. Ferranimal-75M is injected 10 days later in a dose of 2 ml in a combination with an injection of Hyropeptone 5 ml intramuscularly in different points.

EFFECT: method provides higher antioxidative activity of calf's blood serum, reduced pro-oxidant action of iron and incorporated radionuclides, as well as higher iron accessibility in treating and preventing iron-deficiency anaemia in calves exposed to the chronic incorporated radiation.

FIELD: veterinary medicine.

SUBSTANCE: ferroglyukin is administered to new-born calves with iron deficiency anaemia at a dose of 150 mg (2 ml) intramuscularly, twice with an interval of 4 days. Crezacyne 5 mg/kg per day is included in the watering scheme for 4 days, starting simultaneously with the first injection of ferroglyukin. Gamavit is administered intramuscularly once a day in the morning at a dose of 0.05 ml/kg for 4 days, starting simultaneously with ferroglyukin and crezacyne.

EFFECT: method enables to normalise consistently the platelet activity in new-born calves with iron deficiency anaemia during a short period of exposure, transferring it to the level typical of healthy calves, after 4 days of treatment, and to provide long-term maintenance of platelet haemostasis in the optimal mode of operation, eliminating the risk of thrombotic complications in animals and contributing to their normal growth and development.

1 ex

FIELD: metallurgy.

SUBSTANCE: invention relates to casein succinylate of iron (III) wherein iron content varies from 4.5 wt % to 7 wt %, water solubility exceeds 92% while phosphorus-to-nitrogen ratio exceeds 5 wt %.

EFFECT: additionally, invention relates to production of iron (III) and to pharmaceutical composition containing casein succinylate of iron (III).

17 cl, 4 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of organic chemistry, namely to benzoimidazole derivatives of formula (I), as well as to their enantiomers, diastereoisomers, racemates and pharmaceutically acceptable salts, where n equals from 2 to 4, each of R1 substituents is independently selected from H, halogen, -C1-4alkyl, -C1-4pergaloalkyl, trifluoro-C1-4alkoxy, -NO2, -CN, CO2H, -OC1-4alkyl, -SC1-4alkyl, -S(C1-4alkyl)-Rc, -S(O)2(C1-4alkyl)-Rc, -S(O)-C1-4alkyl, -SO2-C1-4alkyl, -S-Rc, -S(O)-Rc, -SO2-Rc, -SO2-NH-Rc, -O-Rc, -CH2-O-Rc, -C(O)NH-Rc, -NRaRb, benzyloxy, phenyl, optionally substituted with one-two Rd, cyanobiphenyl-4-ylmethylsulpfanyl, cyanobiphenyl-4-ylmethanesulphonyl, or -S-(CH2)2-morpholine and two adjacent groups R1 can bind with formation of an aromatic 5-6-membered ring, optionally substituted with one methyl group or two atoms of halogen, optionally containing one or two S or N; Ra and Rb each independently represents C1-4alkyl, -C(O)C1-4alkyl, -C(O)-Rc, -C(O)CH2-Re, C1-4alkyl-Re, -SO2-Rc, -SO2-C1-4alkyl, phenyl, benzyl; or Ra and Rb together with a nitrogen atom, which they are bound with, form a monocyclic 5-6- membered heterocycloalkyl ring, optionally containing one heteroatom, selected from O; Rc represents -C3-8cycloalkyl, phenyl, optionally substituted with one-two Rd, benzyl, optionally substituted with one-three Rd; morpholine; Rd independently represents halogen, -OH, -C1-4alkyl or -C1-4perhalogenalkyl, trifluorine C1-4alcoxy, -OC1-4alkyl, or -O-benzyl optionally substituted with halogen, Re represents -C6heterocycloalkyl, optionally containing one or two of O or N atoms, optionally substituted with a methyl group; R2 and R3 both represent H, -CF3 or C1-3alkyl; each of Z represents a C or N atom, on condition that simultaneously not more than two Z represent N. The invention also relates to particular compounds, a pharmaceutical composition, based on formula (I) compound or a particular said compound, a method of treating diseases, mediated by propyl hydroxylase activity.

EFFECT: novel derivatives of benzimidazole, possessing an inhibiting activity with respect to PHD are obtained.

11 cl, 1 tbl, 186 ex

FIELD: biotechnologies.

SUBSTANCE: in a compound of formula ,

X means N or CH, R1 means hydrogen or cyano, R2 means saturated 4-7-membered residue of heterocyclyl, which is bound through a nitrogen atom that contains 1 to 2 heteroatoms chosen from N and O. Besides, heterocyclyl residue can be replaced with one substituent chosen from a group consisting of C3-C6-cycloalkyl, or with 1-4 fluorine atoms. The invention also refers to a method for obtaining compounds and to a medicine on their basis.

EFFECT: compounds can be used for production of a medicine suitable for being used in a method of treatment or prophylaxis of cardiovascular diseases, cardiac insufficiency, anemia, chronic diseases of kidneys and kidney failure.

16 cl, 1 tbl, 29 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and aims at the simultaneous control of coccidiosis and iron deficiency. The compound comprises triazinones of formulas (I) or (II) wherein R1 means CF3-SO2- or CF3-S-, R2 means CH3, each R4, R5 and R6 means Cl (chlorine) or pharmaceutically acceptable salts thereof, and iron compounds (3+) specified in a group consisting of: multinucleated complex iron (III) and polysaccharide compounds and ammonium-iron (III) citrate. What is also declared is using the above compounds for producing drug preparations.

EFFECT: using the declared group of inventions is effective for the simultaneous control of coccidiosis and iron deficiency; it is accompanied by no adverse phenomena; the compound ingredients have no negative effects on each other; and their biological activity preserves.

17 cl, 15 tbl, 7 ex

FIELD: biotechnologies.

SUBSTANCE: invention relates to production of peptide derivative mimetic of EPO, with the formula: R1-R2-(CH2)n1-R3-(CH2)n2-R4-R5 (I) and its pharmaceutical salts, where R1, R5 are selected from cyclic peptides with sequences SEQ ID NO:5, 6, 7 and 8; n1, n2 represent integer numbers independently selected from 0-10; R2, R4 are selected from -CO or -CH2; R3 is selected from O, S, CH2, N(CH2)n3NHR6, NCO(CH2)n4NHR6, CHOCONH(CH2)n5NHR6, CHSCON(CH2)n5NHR6 or CHNHCON(CH2)n5NHR6; where n3 represents an integer number selected from 1-10, n4 is an integer number selected from 2-10, n5 represents an integer number selected from 2-10, R6 is selected from H or derivatives of metoxyethylene glycol. The produced peptide or its pharmaceutically acceptable salt is used within a pharmaceutical composition for treatment of disorders characterised with EPO deficit, low or defective population of erythrocytes.

EFFECT: invention makes it possible to produce an agonist of EPO receptor having higher biological activity compared to existing EPO mimetics.

15 cl, 2 dwg, 5 tbl, 19 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, and namely to composition for prevention of iron deficiency anemia. Composition for prevention of iron deficiency anemia, which contains source of iron, source of copper, vitamins B1, B3, B6, B9, B12, ascorbic acid, extract from nettle leaves, extract from strawberry leaves, pantohematogen and auxiliary substances, with specified component ratio.

EFFECT: composition makes it possible to extend arsenal of methods for prevention of iron deficiency anemia and is effective.

4 cl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: preparation for normalisation of lipid peroxidation processes in animals comprises, wt %: 2-ethyl-6-methyl-3-hydroxypyridine succinate 20.0-30.0, ascorbic acid 5.0-7.0, selenium (Se°) 0.3-0.5, polyvinylpyrrolidone 3.0-5.0, water for injection - the rest.

EFFECT: antioxidant effect, prevention of excessive formation of lipid peroxidation products, high efficiency in normalisation of functioning of the system of antioxidant protection of animals and the process of lipid peroxidation, low toxicity and ease of administration.

6 dwg, 5 ex

FIELD: biotechnology.

SUBSTANCE: method of production of selenocystine consists in that 1 molar solution of sodium diselenide is prepared by adding 4.5 g of elemental selenium to 10 ml of 1 molar solution of sodium hydroxide (NaOH) in a three-necked flask. Then, 15 ml of distilled water is added and the solution is stirred using a magnetic stirrer. The separately prepared solution of natrium borane (NaBH4) by dissolving it in 25 ml of distilled water is added as drops to the three-necked flask with a suspension of elemental selenium to total decolorization of the solution, and another 4.5 g of elemental selenium are additionally added. 5 g β-chloro-l-alanine are dissolved in distilled water, and the solution is adjusted to pH 9 by adding 1M sodium hydroxide solution. Within 30 minutes the solution of β-chloro-l-alanine is added to the solution of sodium diselenide, located in the three-necked flask and stirred for 12-16 hours at a temperature of +37°C. Then, muriatic acid is added to the resulting solution dropwise to pH 2 and the air purging is carried out for 2-3 hours. The solution is filtered and adjusted with 10 M sodium hydroxide solution to pH 6-6.5. The solution is cooled to +5°C.

EFFECT: increase in the yield ratio and improved purity.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a skin care agent possessing the antifungal properties, containing propolis, ethanol, and a sulphur-containing component, differing the fact that the sulphur-containing component contains elemental nanodispersed sulphur with the components of the agent taken in certain amounts, wt %.

EFFECT: invention provides extending the range of products possessing a wide spectrum of fungicidal action, and promotes the tissue regeneration processes.

3 cl, 3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: children referred to a follow-up group of frequently ill children are prescribed with Multitabs Junior 1 tablet once a day for 30 days within three therapeutic courses every second month and glucosaminyl muramyl dipeptide 1 tablet once a day sublingually for 10 days within three therapeutic courses every 2 months.

EFFECT: method enables lowering a rate of respiratory infections in the frequently ill children by increasing the body resistance to infectious agents and filling the deficiency of vitamins and microelements.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to urology and balneotherapy, and can be used for treating patients with benign prostatic hyperplasia complicated by chronic prostatitis with a dominant symptom of nocturia. That is ensured by performing EHF therapy. The above is combined with an integrated resort treatment: oral administration of carbonate-hydrocarbonate-sulphate sodium-calcium low-mineralised (3.6-3.7 g/l) water in an amount of 280-300 ml three times a day 40-45 minutes before meals. The balneological treatment is prescribed: taking baths with similar mineral water at a temperature of 36-37°C with the exposure of each procedure 15 minutes in the number of 8 procedures every second day. Phytomicroenemas are prescribed in the number of 8 procedures every second day. That is combined with drug therapy with artesine 2 mg/day for 10 days.

EFFECT: method enables the rehabilitation treatment which provides higher adaptation capabilities of the body, reducing the symptoms of the lower urinary tract with the dominant symptom of nocturia from 4-5 to 1-2 urinations a night and improving the quality of life in the patients undergoing the resort therapy It is manifested by the positive improvement of the patients' status as shown by the clinical examination, as well as by IPSS, Q max values.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: complex of biologically active preparations containing glutamic acid, glycine, cysteine, a pectin enterosorbent, a selenium polyvitamin-polymineral complex, a calcium preparation, as well as a cod liver oil preparation rich in nonesterified fatty acids omega 3 is administered. This complex is prescribed as a course of treatment once or twice a year for 4-6 weeks daily in the doses to provide the amounts of glycine of 300 mg, cysteine - 600 mg, glutamic acid - 4 g, selenium - 100 mcg, calcium - 4 g, cod liver oil - 25 ml with 12-15% nonesterified fatty acids omega 3, pectin - 4-5 g, as well as other microelements and vitamins in the doses to fill the normal physiological needs of the body.

EFFECT: lower adverse effects of the general toxic and genotoxic action of nanosilver on the body by normalising lipid peroxidation and the morphofunctional state of the liver and spleen, a lower degree of the DNA fragmentation.

3 tbl

FIELD: medicine.

SUBSTANCE: invention relates to nutritive therapy and is intended for treatment and/or prevention of delayed recall function impairment in subjects who have 24-26 points by Mini-mental State Examination (MMSE). Claimed is application of composition for obtaining product for enteral introduction. Composition contains uridine or uridine phosphate, docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA), phospholipids, choline, vitamin E, vitamin C, selenium, vitamin B12, vitamin B6 and folic acid.

EFFECT: claimed invention provides improvement of memory, in particular, delayed recall function, in patients with 24-26 points by MMSE.

5 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: treating respiratory distress syndrome accompanying neonatal ventilation is ensured by measuring glutathione peroxidase (GSH-Px-3) with underlying drug therapy, and the measured value being less than 2.41 mcmole/l requires including intravenous bolus injections of the preparation Selenase in a therapeutic complex at 10 mcg/kg/day, once a day for 10 days.

EFFECT: method provides increasing the survival rate in reducing a number of complications and a length of treatment by ensuring a lower severity of oxidative stress and a higher antioxidant protection of the body.

1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention represents a pharmacological geroprotective composition, which includes a polyphenol component, vitamins and microelements, humic acids, containing polyphenol components, vitamin C, vitamin A, iron (II) chloride and selenium (IV) dioxide, with the composition components being in a specified ratio in wt %.

EFFECT: increased life expectancy and retardation of tumour development.

2 cl, 3 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to a method of preventing complications of rhinitis or an influenza-like syndrome. The method of preventing complications of rhinitis or the influenza-like syndrome consists in the following: an isoosmotic ionic sea water-based solution with osmolarity, equal to 250-350 mOsm/kg, is introduced daily into each nostril of patients suffering from rhinitis or the influenza-like syndrome, and at the remission stage in the certain regimens.

EFFECT: increased method efficiency.

9 cl, 13 dwg, 13 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to nutritive therapy and is intended for treatment and/or prevention of delayed recall function impairment in subjects who have 24-26 points by Mini-mental State Examination (MMSE). Claimed is application of composition for obtaining product for enteral introduction. Composition contains uridine or uridine phosphate, docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA), phospholipids, choline, vitamin E, vitamin C, selenium, vitamin B12, vitamin B6 and folic acid.

EFFECT: claimed invention provides improvement of memory, in particular, delayed recall function, in patients with 24-26 points by MMSE.

5 cl, 1 tbl, 2 ex

Up!